Pancreatic Cancer Research

ResearcherSun Biopharma, Inc.Active in the last 2 years

Stephen Jacob Pandol

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0818-6017; OpenAlex author ID A5053893604, A5109506910, A5135179885; NIH RePORTER profile ID 1860481. Sources: ClinicalTrials.gov.

Their work

Papers
107 (first author 8, last author 19)
Trials
1 (principal investigator on 1)
Grants
6
Labs led
1
Collaborators
252
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: 3 papers · 2014: 2 papers · 2015: 4 papers · 2016: 6 papers, 2 grants · 2017: 4 papers · 2018: 9 papers · 2019: 8 papers · 2020: 7 papers · 2021: 6 papers · 2022: 18 papers, 1 trial · 2023: 5 papers · 2024: 14 papers, 2 grants · 2025: 8 papers, 1 grant · 2026: 8 papers, 1 grant

Papers 50 of 107

  1. The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) 10 years of past accomplishments and looking forward to the next … First author DOI 10.1016/j.pan.2025.12.023↗
  2. Diabetes secondary to chronic pancreatitis and pancreatic cancer: Observations from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancrea… Co-author DOI 10.1016/j.pan.2026.04.001↗
  3. Towards early detection of pancreatic cancer: The current status of cohort studies by the Diabetes-Pancreatic Ductal AdenoCarcinoma Working Group. Co-author DOI 10.1016/j.pan.2026.04.020↗
  4. Specific targeting of cancer cell mitochondria with a malaria drug improves pancreatic cancer outcome. Co-author DOI 10.1038/s41598-026-66961-9↗
  5. L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 Glut… Co-author DOI 10.1038/s43018-026-01225-z↗
  6. The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC): 10 Years of Past Accomplishments and Looking Forward to the Next… First author DOI 10.1097/mpa.0000000000002629↗
  7. Adult Chronic Pancreatitis Working Group: Goals, Accomplishments and the Path Ahead. A Report From the Consortium for the Study of Chronic Pancreatitis, Diabet… Co-author DOI 10.1097/mpa.0000000000002657↗
  8. Early-onset Pancreatic Cancer is Associated With Better Survival: A SEER Population-Based Analysis. First author DOI 10.1097/mpa.0000000000002702↗
  9. Identification of Tumor-Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcin… Co-author DOI 10.1002/advs.202414982↗
  10. Selective removal of proteins and microvesicles ex vivo from blood of pancreatic cancer patients using bioengineered adsorption filters. Last author DOI 10.1016/j.canlet.2025.217546↗
  11. A Clinical Laboratory Improvement Amendments/College of American Pathologists-Compliant Noninvasive Laboratory-Developed Test for Early Detection of Pancreatic… Co-author DOI 10.1016/j.jmoldx.2024.10.001↗
  12. Circulating tumor cell and oncosome subtypes in portal and peripheral venous circulations may be used for diagnosis and prognostication of pancreatic cancer. Co-author DOI 10.1038/s41698-025-01165-4↗
  13. Significantly higher incidence of circulating fatty objects in portal blood samples compared to peripheral blood samples in patients with pancreatic ductal ade… Last author DOI 10.3389/fonc.2025.1611872↗
  14. Early Detection of Pancreatic Cancer: Current Advances and Future Opportunities. Co-author DOI 10.3390/biomedicines13071733↗
  15. Predicting Pancreatic Ductal Adenocarcinoma Occurrence Up to 10 Years in Advance Using Features of the Main Pancreatic Duct in Pre-Diagnostic CT Scans. Co-author DOI 10.3390/cancers17111886↗
  16. HDAC4/MybL1/YAP novel signaling axis is required for pancreatic cancer metastasis to the liver. Last author DOI 10.7150/ijbs.102132↗
  17. Stromal softness confines pancreatic cancer growth through lysosomal-cathepsin mediated YAP1 degradation. Co-author DOI 10.1007/s00018-024-05466-y↗
  18. Excess pancreatic cancer risk due to smoking and modifying effect of quitting smoking: The Multiethnic Cohort Study. Co-author DOI 10.1007/s10552-023-01811-x↗
  19. Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells. Last author DOI 10.1016/j.freeradbiomed.2024.01.003↗
  20. Promoter Methylation Leads to Hepatocyte Nuclear Factor 4A Loss and Pancreatic Cancer Aggressiveness. Co-author DOI 10.1016/j.gastha.2024.04.005↗
  21. High frequency of germline variants in CFTR identified in PDAC patients enrolled in an expanded panel multi-gene panel testing program. Co-author DOI 10.1016/j.hpb.2024.05.005↗
  22. The burden of young-onset pancreatic cancer and its risk factors from 1990 to 2019: A systematic analysis of the global burden of disease study 2019. Co-author DOI 10.1016/j.pan.2023.12.005↗
  23. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. Co-author DOI 10.1016/j.tranon.2024.102109↗
  24. Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery. Co-author DOI 10.1038/s41698-024-00521-0↗
  25. Determining the efficacy of ExThera Seraph100 blood filtration in patients diagnosed with pancreatic cancer through the liquid biopsy. Last author DOI 10.1038/s44276-024-00069-3↗
  26. Ascites Is a Poor Prognostic Factor in Advanced Pancreatic Adenocarcinoma and May Be Undertreated: A Prospective Cohort Study. Co-author DOI 10.14309/ctg.0000000000000719↗
  27. An insight to PDAC tumor heterogeneity across pancreatic subregions using computed tomography images. Co-author DOI 10.3389/fonc.2024.1378691↗
  28. Evaluation of urinary C-reactive protein as an early detection biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2024.1450326↗
  29. The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analy… Co-author DOI 10.3390/cancers16050971↗
  30. Upregulated Matrisomal Proteins and Extracellular Matrix Mechanosignaling Underlie Obesity-Associated Promotion of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers16081593↗
  31. Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice. Co-author DOI 10.1038/s41598-023-43498-9↗
  32. Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001-2018. Co-author DOI 10.1053/j.gastro.2023.01.022↗
  33. Supraphysiological glutamine as a means of depleting intracellular amino acids to enhance pancreatic cancer chemosensitivity Co-author DOI 10.21203/rs.3.rs-3647514/v1↗
  34. Pancreatic Cancer Incidence Trends by Race, Ethnicity, Age and Sex in the United States: A Population-Based Study, 2000-2018. Co-author DOI 10.3390/cancers15030870↗
  35. Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers15113020↗
  36. Novel DZ-SIM Conjugate Targets Cancer Mitochondria and Prolongs Survival in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/adtp.202200021↗
  37. Uniting epidemiology and experimental models: pancreatic steatosis and pancreatic cancer. First author DOI 10.1016/j.ebiom.2022.103996↗
  38. Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis. Co-author DOI 10.1016/j.pan.2021.09.015↗
  39. Rising Incidence and Racial Disparities of Early-Onset Pancreatic Cancer in the United States, 1995-2018. Co-author DOI 10.1053/j.gastro.2022.03.011↗
  40. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. Co-author DOI 10.1053/j.gastro.2022.06.027↗
  41. HDAC4 Mediates Smoking-Induced Pancreatic Cancer Metastasis. Co-author DOI 10.1097/mpa.0000000000001998↗
  42. Chemical Exchange Saturation Transfer for Pancreatic Ductal Adenocarcinoma Evaluation. Co-author DOI 10.1097/mpa.0000000000002059↗
  43. Prediction of Pancreatic Cancer in Diabetes Patients with Worsening Glycemic Control. Co-author DOI 10.1158/1055-9965.epi-21-0712↗
  44. Integration of metabolites from meta-analysis with transcriptome reveals enhanced SPHK1 in PDAC with a background of pancreatitis. Co-author DOI 10.1186/s12885-022-09816-6↗
  45. Correction: Integration of metabolites from meta-analysis with transcriptome reveals enhanced SPHK1 in PDAC with a background of pancreatitis. Co-author DOI 10.1186/s12885-022-09920-7↗
  46. Artificial intelligence and imaging for risk prediction of pancreatic cancer: a narrative review. Co-author DOI 10.21037/cco-21-117↗
  47. Predicting pancreatic ductal adenocarcinoma using artificial intelligence analysis of pre-diagnostic computed tomography images. Co-author DOI 10.3233/cbm-210273↗
  48. Multitasking dynamic contrast enhanced magnetic resonance imaging can accurately differentiate chronic pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2022.1007134↗
  49. Risk prediction of pancreatic cancer using AI analysis of pancreatic subregions in computed tomography images. Co-author DOI 10.3389/fonc.2022.1007990↗
  50. Circulating Fatty Objects and Their Preferential Presence in Pancreatic Cancer Patient Blood Samples. Last author DOI 10.3389/fphys.2022.827531↗

Trials 1

  1. Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC) Principal investigator NCT04700488↗

Grants 6

  1. Cedars Sinai Center for the Chronic Pancreatitis Clinical Research Consortium U01DK108314↗
  2. Predicting Pancreatic Ductal Adenocarcinoma (PDAC) Through Artificial Intelligence Analysis of Pre-Diagnostic CT Images R01CA260955↗
  3. Core 1: Animal and Cell Model Core P01CA236585↗
  4. A Pilot Clinical Trial of Paricalcitol for Chronic Pancreatitis R01DK132631↗
  5. Animal Core P01CA163200↗
  6. Evaluation of SBP-101 for the Treatment of Acute Pancreatitis R41DK111337↗

Closest collaborators

The 25 strongest of 252 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mouad Edderkaoui · 28 shared papers, 2011–2026 · strength 3.52
  2. Debiao Li · 13 shared papers, 1 shared grant, 2020–2025 · strength 2.78
  3. Simon K. Lo · 16 shared papers, 2014–2025 · strength 2.69
  4. Andrew Eugene Hendifar · 17 shared papers, 2014–2026 · strength 2.52
  5. Christopher E Forsmark · 9 shared papers, 2016–2026 · strength 2.46
  6. Arsen Osipov · 13 shared papers, 2021–2026 · strength 2.28
  7. Srinivas Gaddam · 13 shared papers, 2020–2025 · strength 2.21
  8. Mark Goodarzi · 5 shared papers, 1 shared grant, 2016–2026 · strength 1.92
  9. Nicholas N. Nissen · 12 shared papers, 2014–2025 · strength 1.77
  10. Jun Gong · 11 shared papers, 2014–2026 · strength 1.76
  11. Guido Eibl · 11 shared papers, 2 shared grants, 2012–2024 · strength 1.75
  12. Christie Y. Jeon · 13 shared papers, 2014–2025 · strength 1.47
  13. Ruoxiang Wang · 7 shared papers, 2017–2026 · strength 1.36
  14. Temel Tirkes · 4 shared papers, 1 shared grant, 2018–2026 · strength 1.28
  15. Veronica Wendy Setiawan · 10 shared papers, 2019–2024 · strength 1.28
  16. Omer Hany Miligy Elmadbouh · 6 shared papers, 2022–2026 · strength 1.21
  17. Touseef Ahmad Qureshi · 6 shared papers, 2022–2025 · strength 1.16
  18. Phil A. Hart · 9 shared papers, 2016–2026 · strength 1.13
  19. Vay Liang W. Go · 4 shared papers, 2 shared grants, 2016–2024 · strength 1.05
  20. Marc T Goodman · 1 shared paper, 1 shared grant, 2015–2024 · strength 0.97
  21. Lixia Wang · 6 shared papers, 2020–2025 · strength 0.93
  22. Walter Gwang-Up Park · 6 shared papers, 2018–2026 · strength 0.93
  23. Aurelia Lugea · 9 shared papers, 2012–2025 · strength 0.91
  24. Yan Ou · 4 shared papers, 2022–2026 · strength 0.90
  25. Evan L Fogel · 5 shared papers, 2018–2026 · strength 0.86

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.